Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Mohammad O Hussaini, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD MS, David A. Sallman, MD, Rami Komrokji, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140885

Published: 2020

Journal Articles

Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)

Jinming Song, MD PhD, Hailing Zhang, MD, Xiaohui Zhang, MD PhD, Mohammad Hussaini, MD, Ning Dong, MD, Lynn C Moscinski, Kenneth H. Shain, MD PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Ling Zhang, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141656

Published: 2020

Journal Articles

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

Quinto J Gesiotto, MD, David M Swoboda, MD, Najla E. Al Ali, Eric Padron, MD, Andrew T. Kuykendall, MD, Jinming Song, MD PhD, Chetasi Talati, MD, Kendra L. Sweet, MD MS, Jeffrey E. Lancet, MD, Rami Komrokji, MD, David A. Sallman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140861

Published: 2020

Journal Articles

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Chetasi Talati, MD, Hannah H Asghari, MD, Jinming Song, MD PhD, Mohammad Hussaini, MD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Asmita Mishra, MD, Kendra L. Sweet, MD

Blood (2019) 134 (Supplement_1): 2052.

https://doi.org/10.1182/blood-2019-129742

Published: 2019

Journal Articles

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

Onyee Chan, MD, Anthony Hunter, MD, Chetasi Talati, MD, David A Sallman, MD, Hannah Asghari, MD BS, Jinming Song, MD PhD, Mohammad Hussaini, MD, Nelli Bejanyan, MD, Hany Elmariah, MD MS, Andrew T Kuykendall, MD, Eric Padron, MD, Rami S. Komrokji, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Asmita Mishra, MD

Blood (2019) 134 (Supplement_1): 149.

https://doi.org/10.1182/blood-2019-131530

Published: 2019

Journal Articles

The Prognostic Significance of ASXL1/EZH2 Co-Mutation in Comparison with ASXL1 or EZH2 Mutation Alone in Myelodysplastic Syndromes

Pukhraz Basra, MBBS, David Gajzer, MD, Mohammad O Hussaini, MD, Hailing Zhang, MD, Lynn C. Moscinski, MD, Eric Padron, MD, David A Sallman, MD, Rami S. Komrokji, MD, Ling Zhang, MD, Jinming Song, MD PhD

Blood (2019) 134 (Supplement_1): 5428.

https://doi.org/10.1182/blood-2019-132070

Published: 2019

Journal Articles

SF3B1/DNMT3A Double Mutations Are Associated with Better Prognosis Than DNMT3A Mutation Alone in Myeloid Neopasms

Jinming Song, MD PhD, Mohammad Hussaini, MD, Lynn C. Moscinski, MD, Ling Zhang, MD, Xiaohui Zhang, MD PhD, Haipeng Shao, MD, Hailing Zhang, MD

Blood (2019) 134 (Supplement_1): 5029.

https://doi.org/10.1182/blood-2019-124040

Published: 2019

Journal Articles

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Mohammad O Hussaini, MD, Jinming Song, MD PhD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Sayeef Mirza, MDMPH, Ling Zhang, MD

Blood (2019) 134 (Supplement_1): 5442.

https://doi.org/10.1182/blood-2019-128997

Published: 2019

Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD

Blood (2019) 134 (Supplement_1): 3189.

https://doi.org/10.1182/blood-2019-131451

Published: 2019

Journal Articles

Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts

David M Swoboda, MD, Jung-Hoon Lee, MD, Onyee Chan, MD, Rami S. Komrokji, MD, Najla Al Ali, M.Sc, Eric Padron, MD, Alan F. List, MD, Mohammad O Hussaini, MD, Jinming Song, MD PhD, David A Sallman, MD

Blood (2019) 134 (Supplement_1): 4244.

https://doi.org/10.1182/blood-2019-124772

Published: 2019

Journal Articles

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Blood (2019) 134 (Supplement_1): 4621.

https://doi.org/10.1182/blood-2019-130922

Published: 2019

Journal Articles

Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival

David A Sallman, MD, Najla Al Ali, M.Sc, Seongseok Yun, MD PhD, Eric Padron, MD, Jinming Song, MD PhD, Mohammad Omar Hussaini, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Alan F. List, MD, Rami S. Komrokji, MD

Blood (2018) 132 (Supplement 1): 1817.

https://doi.org/10.1182/blood-2018-99-117297

Published: 2018

Journal Articles

TP53 Mutations Are a Rare Event in Primary Myelofibrosis, Associated with TET2 Mutations, and Suggest Poor Clinical Outcome

Mohammad Omar Hussaini, MD, Jinming Song, MD PhD, Rami S. Komrokji, MD, David A Sallman, MD, Andrew Kuykendall, MD, Eric Padron, MD, Sayeef Mirza, MD MPH, Ling Zhang, MD

Blood (2017) 130 (Supplement 1): 5270.

https://doi.org/10.1182/blood.V130.Suppl_1.5270.5270

Published: 2017

Journal Articles

Presence of MDS-Related Cytogenetic Abnormalities Predicts Worse Outcomes in Primary Myelofibrosis Compared to Patients with Del(13q)

Mohammad Omar Hussaini, MD, Jinming Song, MD PhD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Andrew Kuykendall, MD, Sayeef Mirza, MD MPH, Ling Zhang, MD

Blood (2017) 130 (Supplement 1): 5275.

https://doi.org/10.1182/blood.V130.Suppl_1.5275.5275

Published: 2017

Journal Articles

EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome

Kathy L Mcgraw, PhD, Johnny Nguyen, Najla Alali, MS, Jinming Song, MD PhD, David Sallman, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Daihui Qin, P.K. Epling-Burnette, PhD, Lynn C. Moscinski, MD, Rami S. Komrokji, MD, Alan F List, MD, Ling Zhang, MD

Blood (2016) 128 (22): 4305.

https://doi.org/10.1182/blood.V128.22.4305.4305

Published: 2016

Journal Articles

Clinical Utility of Molecular Profiling in Higher Risk MDS Treated with Azacitidine: Can We Tailor Therapy Accordingly?

David Sallman, MD, Eric Padron, MD, Jinming Song, MD PhD, Mohammad Omar Hussaini, MD, Christine Vaupel, PhD, Najla H Al Ali, Jeffrey E. Lancet, MD, Jeff Hall, PhD, Alan F List, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1984.

https://doi.org/10.1182/blood.V128.22.1984.1984

Published: 2016

Journal Articles

Mutation Landscape in Myelofibrosis: Assessment of Frequency and Correlation with Clinical Factors and Outcomes

Andrew Kuykendall, MD, Chetasi Talati, MD, Najla H Al Ali, Eric Padron, MD, David Sallman, MD, Jinming Song, MD PhD, Ling Zhang, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Alan F. List, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1946.

https://doi.org/10.1182/blood.V128.22.1946.1946

Published: 2016

Journal Articles

Validation of Genomic-Based Risk Models in Myelofibrosis and Proposal of Age-Independent Disease-Specific Models

Andrew Kuykendall, MD, Chetasi Talati, MD, Najla Al Ali, Eric Padron, MD, David Sallman, MD, Jinming Song, MD PhD, Ling Zhang, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Alan F. List, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1947.

https://doi.org/10.1182/blood.V128.22.1947.1947

Published: 2016

Journal Articles

Large Cohort Analysis of Targeted NGS Mutations and Cytogenetic Abnormalities in Hematologic Malignancies

Mohammad Omar Hussaini, MD, Haipeng Shao, MD, PhD, Lynn C. Moscinski, MD, Jinming Song, MD PhD

Blood (2015) 126 (23): 1406.

https://doi.org/10.1182/blood.V126.23.1406.1406

Published: 2015

NARROW

PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies

Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)

Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies

RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation

The Prognostic Significance of ASXL1/EZH2 Co-Mutation in Comparison with ASXL1 or EZH2 Mutation Alone in Myelodysplastic Syndromes

SF3B1/DNMT3A Double Mutations Are Associated with Better Prognosis Than DNMT3A Mutation Alone in Myeloid Neopasms

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival

TP53 Mutations Are a Rare Event in Primary Myelofibrosis, Associated with TET2 Mutations, and Suggest Poor Clinical Outcome

Presence of MDS-Related Cytogenetic Abnormalities Predicts Worse Outcomes in Primary Myelofibrosis Compared to Patients with Del(13q)

EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome

Clinical Utility of Molecular Profiling in Higher Risk MDS Treated with Azacitidine: Can We Tailor Therapy Accordingly?

Mutation Landscape in Myelofibrosis: Assessment of Frequency and Correlation with Clinical Factors and Outcomes

Validation of Genomic-Based Risk Models in Myelofibrosis and Proposal of Age-Independent Disease-Specific Models

Large Cohort Analysis of Targeted NGS Mutations and Cytogenetic Abnormalities in Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only